Category: PharmaceuticalsSyndicate content

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

November 17, 2014 by Brad Perriello

Allergan agrees to a $66 billion takeover bid from Actavis, thwarting a hostile takeover bid by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management.

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

Source: Allergan near $66B buyout to escape Valeant, Ackman

November 17, 2014 by MassDevice

Allergan is close to sealing a deal worth nearly $66 billion with Actavis and giving the slip to a hostile takeover bid from Valeant Pharmaceuticals and William Ackman's Pershing Square hedge fund.

Source: Allergan near $66B buyout to escape Valeant, Ackman

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Capricor buys Medtronic peptide patent rights

November 12, 2014 by Val Kennedy

Capricor Therapeutics acquires Medtronic's patent rights for the formulation and delivery of natriuretic peptides to treat heart failure.

Capricor buys Medtronic peptide patent rights

Capricor Therapeutics said it acquired Medtronic's (NYSE:MDT) patent rights for the formulation and delivery of natriuretic peptides.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Salix inventory snafu sinks deal with Allergan

November 7, 2014 by MassDevice

Allergan backed out of a deal to merger with Salix Pharmaceuticals, which would have likely stymied Valeant's hostile takeover, after it found out that Salix has enough inventory to last months, not weeks.

Salix inventory issues sink deal with Allergan

Allergan in talks with 3rd-party acquirer

November 6, 2014 by MassDevice

Allergan confirms it's in talks with a 3rd-party buyer, said to be Actavis, in the run up to a December showdown with hostile takeover bidders Valeant Pharmaceuticals and Pershing Square Capital Management.

Allergan in talks with 3rd-party acquirer

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Court leaves door open for Ackman's vote at Allergan meeting

November 4, 2014 by MassDevice

A federal judge in California rules that hedge fund mogul William Ackman's Pershing Square Capital Management and Valeant Pharmaceuticals may get their vote at a special meeting of Allergan shareholders slated for next month.

Court leaves door open for Ackman's vote at Allergan meeting

Ackman (Reuters/Eduardo Munoz).
Click to enlarge.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp